Allogenetics–SEVERAL: investment, 202408 first financing round €3.4m led by NBank Capital + Carma Fund

	Period	2024-08-29
	Money taker	Allogenetics GmbH
	Money source	SEVERAL
	Product	immunology
	Product 2	venture capital
	Person	Leikert, Christian (Carma Fund 202206– General Partner before Creathor Ventures + Future Capital)
	Person 2	Hauck, Susanne (Lower Saxony (govt) 202408 Investment Manager at NBank Capital)

Allogenetics GmbH. (9/2/24). "Press Release: The Future of Organ Transplantation Receives a Significant Boost. Allogenetics GmbH Successfully Completes Its First Funding Round, Securing €3.4 Million in Financing".

The Future of Organ Transplantation Receives a Significant Boost: Allogenetics GmbH Successfully Completes Its First Funding Round, Securing €3.4 Million in Financing

The round was led by NBank Capital, the subsidiary of the Investment and Development Bank of Lower Saxony (NBank), as joint lead investor along with the Carma Fund and several business angels.

Many people die after a transplant due to the severe side effects of taking immunosuppressants. These drugs prevent the body from rejecting the foreign organ, however at the same time, by suppressing the patient´s immune defenses, they open the door to deadly diseases like infections and cancer. To make the use of immunosuppressants dispensable, the Allogenetics GmbH team aims to genetically modify the organs prior to transplantation so that they are no longer attacked by the immune system.

The goal of the spin-off from the Hannover Medical School (MHH) is to sustainably improve the quality of life for transplant patients by decreasing their risk of contracting deadly illnesses. Allogenetics' first-in-class therapeutic makes up a completely new approach to solving the problem of organ rejection and creates immunological invisibility of the donor organ. This disruptive innovation offers a new dimension in organ transplantation: invisible organs instead of lifelong immunosuppression.

The founders are Prof. Dr. Rainer Blasczyk, head of the Institute for Transfusion Medicine and Transplant Engineering (ITT), Prof. Dr. Constanca Ferreira de Figueiredo, professor of allogeneic cell therapy at ITT, and economist Philipp Langrehr.

As of September 1, Dr. Frank Schnieders took over the position of CEO. He is a biochemist by training and serial entrepreneur with over 20 years of experience in biotechnology focused on viral gene therapeutics and immunology. He started his career at Medical School Hannover with a PhD in Human Genetics.

Allogenetics is currently preparing for the clinical trial and hopes to receive the green light from authorities to proceed within less than two years.

Further information about Allogenetics can be found here: www.allogenetics.de.

Record changed: 2024-09-03

Picture Berlin Partner Top News CareSyntax Raises $61m for Bio Cheese 650x200px

More documents for Allogenetics GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)